Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.336NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.400.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.400.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.537NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.537NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.548NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.548NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.24.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.24.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.30NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.188NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.188NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.39NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-3888.18US
B.1.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.50NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.50NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.494NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-22948.2US
B.1.494NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.167NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-13863.4US
B.1.167NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.485NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.485NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.119NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.119NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.276NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.276NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.111NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.111NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.27NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.381NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.381NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.32NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
C.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AE.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.516NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.516NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.526NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.526NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.279NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.279NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
B.1.187NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.187NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
D.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
D.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AE.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.110.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used